Extremes of Coronary Artery Disease and Normality:CAD Extremes

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age21-99
SponsorNational Heart Centre Singapore

About this trial

In the field of cardiovascular medicine, there are two differing groups of patients that remain puzzling to clinicians: patients who are not expected to have coronary artery disease (CAD) yet are diagnosed with significant CAD; and those who are have multiple risk factors for CAD but do not have CAD. Bats exhibit unique phenotypes including long lifespans and likely reduced atherosclerosis. Prior work has identified multiple molecular mechanisms of suppressing the activation of inflammasomes, causally linked to atherosclerosis. The investigators hypothesize there are different molecular markers that confer protection or increased risk for CAD, some of which may be similar to bats. Thus, the aim of this study is to identify molecular markers that contribute to or are protective against acute coronary syndrome (ACS) through analyzing the genetics, peripheral blood and atherosclerotic samples from both extreme patient groups using single-cell RNA sequencing and multi-omics approach. In addition, novel anti-atherosclerotic mechanisms and factors from bat studies will be assessed in the human samples. Identification of novel targets that prevent or cause CAD has the potential to aid in the early identification of high-risk patients and development of new therapeutics to combat this growing epidemic. To conduct this study, patients who have undergone a coronary angiogram or a CT coronary angiogram that fall into the both extremes will be recruited and blood samples will be taken for the above analysis. These will be compared to a group of controls (low risk without disease and high risk with disease).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Evidence of significant CAD a. Coronary angiogram or CT coronary angiogram with documented stenosis >=50% in left main or >=70% in major epicardial vessel or major branches (LAD, LCX, RCA)

Age </= 45 for males and </= 50 for females

Absence of diabetes mellitus

Absence of tobacco use

Disqualifiers

Prior history of cancer (excludes pre-cancerous lesions)

Expected life expectancy less than 1 year

Known autoimmune disease

Psychiatric illness

Trial population

Coronary Artery Disease patients with high risk factors/ low risk factors No Coronary Artery disease but with high risk factors

Trial design

Design model

Case-control

Time perspective

Other

Treatments tested in this trial

  • Blood draw

    Procedure/Surgery

    2 6ml blood tubes will be collected from patient

Treatment groups

1,500 Participants
are divided into 4 treatment groups
Group A: Group 1 (significant CAD, low risk factors)1 intervention
Group B: Group 2 (minor CAD, high risk factors)1 intervention
Group C: Group 3 (signifcant CAD, high risk factors)1 intervention
Group D: Group 4 Control group1 intervention

Trial outcomes

Primary outcomes

1

Using sequencing analysis to develop treatment to protect against Coronary artery disease

To use advanced genomic, metabolomics, proteomic and single-cell RNA sequencing (scRNA-seq) analysis to understand novel factors influencing the development of coronary artery disease, as well as protection against coronary artery disease

Time frame
5 years
2

Develop treatment for Coronary artery disease

To aid in the development of novel preventive and treatment strategies for coronary artery disease

Time frame
5 years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

National Heart Centre Singapore

Lead sponsor

Duke-NUS Graduate Medical School

Collaborator